Hank Safferstein is a seasoned and experienced executive in the life sciences industry.
Dr. Safferstein is an Executive-in-Residence with the Pittsburgh Life Sciences Greenhouse. In addition to, Hank is also President and CEO of Cognition Therapeutics, a PLSG portfolio company imported from San Francisco. Cognition Therapeutics Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other neuro-degenerative diseases of the human brain.
Prior to joining PLSG in 2007, Dr. Safferstein served as Vice President, Business Development, for Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products. Prior to joining Omrix, he was Executive Vice President, Corporate Development for TransPharma Medical, a privately held medical device company. Prior to that, Hank served as Vice President, Business Development for Acorda Therapeutics, a central nervous system drug development and marketing company. Prior to joining Acorda Therapeutics, he served in various business development and marketing positions with Bristol-Myers Squibb, a multinational pharmaceutical company. From 1991-1997, he was Director, Technology Transfer at the National Heart, Lung and Blood Institute and Cooperative Venture Manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and was an NIH Post-Doctoral Fellow and Fellow of the Multiple Sclerosis Society.